Human papillomavirus (HPV) cancers are expected to be major global health concerns in the
upcoming decades. The growth of HPV-positive cancer cells depends on the consistent expression of
oncoprotein which has been poorly taken into account in the cellular communication. Among them,
E6/E7 oncoproteins are attractive therapeutic targets as their inhibition rapidly leads to the onset of aging
in HPV-positive cancer cells. This cellular response is associated with the regeneration of p53, pRb
anti-proliferative proteins as well as the mTOR signaling pathway; hence, the identification of involved
and application of E6/E7 inhibitors can lead to new therapeutic strategies. In the present review, we focused
on the pathogenicity of E6/E7 Proteins of human papillomavirus and their roles associated with
the cervical cancer.